These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 4310839)

  • 21. Location, location, timing: analysis of cytomegalovirus epitopes for neutralizing antibodies.
    Schrader JW; McLean GR
    Immunol Lett; 2007 Sep; 112(1):58-60. PubMed ID: 17714794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preparation of immune rabbit sera with neutralizing activity against human cytomegalovirus and varicella-zoster virus.
    Martos LM; Ablashi DV; Gilden RV; Sigüenza RF; Hampar B
    J Gen Virol; 1970; 7(2):169-71. PubMed ID: 4316778
    [No Abstract]   [Full Text] [Related]  

  • 23. Potentiating-factor dependency and molecular size of neutralizing antibodies produced in bovine parainfluenza 3 virus infection.
    Kono M
    Natl Inst Anim Health Q (Tokyo); 1970; 10(3):129-36. PubMed ID: 4320654
    [No Abstract]   [Full Text] [Related]  

  • 24. Differentiation of human IgM subclasses by the ability to interact with a factor resembling the first component of complement.
    Mackenzie MR; Warner NL; Linscott WD; Fudenberg HH
    J Immunol; 1969 Sep; 103(3):607-12. PubMed ID: 4979781
    [No Abstract]   [Full Text] [Related]  

  • 25. Differentiation between acute primary and recurrent human cytomegalovirus infection in pregnancy, using a microneutralization assay.
    Eggers M; Metzger C; Enders G
    J Med Virol; 1998 Dec; 56(4):351-8. PubMed ID: 9829641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of natural cytotoxic rabbit antibody by human IgM: production of nontoxic rabbit serum for use as complement source.
    Herberman RB
    J Immunol; 1970 Apr; 104(4):805-9. PubMed ID: 4986162
    [No Abstract]   [Full Text] [Related]  

  • 27. Physical properties of cytomegalorvirus immune complexes prepared with IgG neutralizing antibody, anti-IgG, and complement.
    Rundell BB; Betts RF
    J Immunol; 1980 Jan; 124(1):337-42. PubMed ID: 6243148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rabbit 19S antibodies with allotypic specificities of the a-locus group.
    Stemke GW; Fischer RJ
    Science; 1965 Dec; 150(3701):1298-303. PubMed ID: 5856998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of temperature on the reactivity of guinea-pig complement with gamma G and gamma M haemolytic antibodies.
    Frank MM; Gaither T
    Immunology; 1970 Dec; 19(6):967-74. PubMed ID: 5487543
    [No Abstract]   [Full Text] [Related]  

  • 30. [Virus-neutralizing antibody and mechanism of its action (author's transl)].
    Yoshino K
    Tanpakushitsu Kakusan Koso; 1974 Sep; 19(10):956-64. PubMed ID: 4373786
    [No Abstract]   [Full Text] [Related]  

  • 31. [Orientational studies for the demonstration of various antibodies against fungi in animal and human serums. I. The appearance of 19S and 7S antibodies in animal immune serums against various inhaled molds].
    Tomsíková A; Seeliger HP
    Mykosen; 1968 Nov; 11(11):785-92. PubMed ID: 4991010
    [No Abstract]   [Full Text] [Related]  

  • 32. Anti-human cytomegalovirus nuclear antigen antibodies of different immunoglobulin classes.
    Czeglédy J; Gergely L; Váczi L; Vályi-Nagy T
    Acta Virol; 1982 Jan; 26(1-2):73-8. PubMed ID: 6124112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Laboratory diagnosis of congenital cytomegalovirus infections].
    McLaughlin B; Martineau B
    Union Med Can; 1973 Jan; 102(1):130-3. PubMed ID: 4350376
    [No Abstract]   [Full Text] [Related]  

  • 34. Determination of 19S and 7S components in an anti-hapten antibody.
    Kontiainen S; Mäkelä O
    Ann Med Exp Biol Fenn; 1967; 45(4):472-6. PubMed ID: 4877586
    [No Abstract]   [Full Text] [Related]  

  • 35. Bovine immune response to Theileria parva: neutralizing antibodies to sporozoites.
    Musoke AJ; Nantulya VM; Buscher G; Masake RA; Otim B
    Immunology; 1982 Apr; 45(4):663-8. PubMed ID: 6802745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SV40 neutralizing antibodies in the sera of man and experimental animals.
    Horváth LB
    Acta Virol; 1972 Mar; 16(2):141-6. PubMed ID: 4401071
    [No Abstract]   [Full Text] [Related]  

  • 37. [The latex-IgM-test in virus diagnostic: determination of cytomegalovirus antibodies (author's transl)].
    Schmidt WA; Klein M; Brade L
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1981; 250(1-2):25-33. PubMed ID: 6274108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of antichlamydial IgM antibody by IgG antibody in immunofluorescence tests.
    Juchau SV; Linscott WD; Schachter J; Jawetz E
    J Immunol; 1972 Jun; 108(6):1563-9. PubMed ID: 4624176
    [No Abstract]   [Full Text] [Related]  

  • 39. Antisera to human cytomegaloviruses prepared in the guinea pig: specific immunofluorescence and complement fixation tests.
    Huang YT; Huang ES; Pagano JS
    J Immunol; 1974 Feb; 112(2):528-32. PubMed ID: 4360544
    [No Abstract]   [Full Text] [Related]  

  • 40. DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates.
    Shen S; Wang S; Britt WJ; Lu S
    Vaccine; 2007 Apr; 25(17):3319-27. PubMed ID: 17287056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.